Curing Macular Degeneration

Through Tissue Engineering Innovation

Tissue Engineering Innovations

Solutions To Global Crisis

Macular degeneration is a leading cause of vision loss in Americans 60 years of age and older. As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050. The number of people living with macular degeneration is expected to reach 196 million worldwide by 2020 and increase to 288 million by 2040.

Estimates of the global cost of visual impairment due to age-related macular degeneration is $343 billion, including $255 billion in direct health care costs.

Degeneration Crisis

Current treatments cannot cure macular degeneration. Surgery, Eye Injections, Eye Supplements and Gene Therapy can slow the progression, and are often expensive. Gene therapy for example costs $850,000 for both eyes to be treated.

Mesogen Will Solve This Crisis

  • Mesogen will be a provider of autologous engineered Retinal Pigment Epithelium (RPE) cell patches for transplant. This will be a curative treatment.

  • These patches can be grown in about 2 months with our proprietary process, and the patient's own cells.

  • The patient will not require long-term anti-rejection drugs and will have a better quality of life with less complications.  

How it Works

Bone Marrow Aspiration
Stem Cell Isolation
Stem Cell Expansion
Stem Cell Differentiation to RPE Cells
Completed RPE Patch
RPE Patch Transplant

A Cure Is Coming

Take The First Step Towards Your Future

Take control of your future and get in touch with us today to explore how Mesogen can assist you. Whether you’re a physician or a patient, we’re actively engaged in different stages of development and would love to discuss how we can support your goals. Don’t hesitate, reach out today!